vaccines
Valneva Scotland supports local cancer charity Team Jak FoundationÂ
October 31, 2024Support Services Oncology, Scotland, Valneva Scotland, cancer charity, paediarics, vaccines
Valneva Scotland, the country’s largest vaccine producer, has partnered with local West Lothian-headquartered charity, Team Jak, helping towards the organisation’s …
Pfizer releases results for severe RSV-associated LRTD treatment study
August 13, 2024Clinical Trial Services, Research and Development Immunology, Pfizer, autoimmune, clinical trial, respiratory, vaccines
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical trial into the safety and …
Merck plans to conduct trials for HPV vaccines
March 13, 2024Research and Development Immunology, Merck, vaccines
Merck, known as MSD outside of the US and Canada, has announced that it is planning to initiate clinical development …
Measles: the UK’s next epidemic?
March 6, 2024MMR, measles, vaccines
Recently, the UK has seen a rapid increase in the number of cases of measles, along with a drop in …
AstraZeneca to acquire Icosavax for up to $1.1bn
December 12, 2023Business Services AstraZeneca, Icosavax, Immunology, acquisition, immunology, vaccines
AstraZeneca has announced that it has entered into a definitive agreement to acquire Icosavax for approximately $15 per share or …
Janssen and Sanofi enter agreement for potential vaccine programme
October 5, 2023Business Services Immunology, Janssen, Sanofi, e coli, vaccines
Janssen Pharmaceuticals, a Johnson & Johnson company, has announced a development and commercialisation agreement with Sanofi for Janssen’s extraintestinal pathogenic …
Moderna shares data from phase 1/2 trial for combination flu and COVID-19 vaccine
October 5, 2023Research and Development COVID-19, Immunology, Moderna, clinical trial, influenza, vaccines
Moderna has announced positive interim results from the phase 1/2 trial of mRNA-1083, its investigational combination vaccine against influenza and …
BactiVac funds development of bacterial vaccines to prevent infections against antimicrobial resistance
September 28, 2023Research and Development AMR, BactiVac, Immunology, vaccines
The University of Birmingham hosted Bacterial Vaccines Network has been awarded £1.4m in funding from the UK government to accelerate …
GSK and Save the Children extend partnership for unvaccinated children
September 15, 2023Medical Communications GSK, Immunology, childhood vaccination, vaccines
GSK and Save the Children have announced that they will be renewing their partnership for an additional five years. GSK …
Vaxxas opens manufacturing facility for needle-free vaccine patch
June 19, 2023Research and Development Immunology, Vaxxas, manufacturing, needle-free vaccines, vaccines
Clinical stage biotech company Vaxxas has announced that it is opening a biomedical manufacturing facility in Brisbane, Australia, for the …
CureVac and GSK begin phase 1 trial for mRNA flu vaccine candidates
May 9, 2023Medical Communications CureVac, GSK, Virology, clinical trial, mrna, vaccines
CureVac and GSK have announced that the first patient in the phase 1 section of their combined phase 1/2 trial …
Sanofi complete acquisition of mRNA company Translate Bio
September 15, 2021Research and Development 2021, 3.2 billion, COVID-19, Sanofi, Translate Bio, acquisition, mrna, vaccines
French pharma giants Sanofi continues its run of acquisitions in 2021 by completing the deal for Translate Bio, a Massachusetts-based …
UK COVID vaccine update
June 16, 2021Research and Development COVID-19, UK, care homes, children, government, vaccines
Care home staff vaccinations to be compulsory COVID-19 vaccinations among care home staff are to become mandatory, the Guardian has …
World’s first COVID-19 vaccine booster study launches in UK
May 20, 2021COVID-19, UK government, booster vaccine, clinical trial, vaccines
The UK government has announced that thousands of volunteers will receive a booster COVID-19 vaccine in a new clinical trial, …
Novavax announces vaccine’s high efficacy against original and variant COVID-19 strains
March 12, 2021Medical Communications COVID-19, Novavax, vaccines
Novavax has announced final efficacy of 96.4% against mild, moderate, and severe disease caused by the original COVID-19 strain in …
Latest content
